Literature DB >> 10395948

Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein.

C Marbeuf-Gueye1, D Ettori, W Priebe, H Kozlowski, A Garnier-Suillerot.   

Abstract

Multidrug resistance (MDR) in model systems is known to be conferred by two different integral proteins, the 170-kDa P-glycoprotein (Pgp) and the 190-kDa multidrug resistance-associated protein (MRP1). One possible pharmacological approach to overcome drug resistance is the use of specific inhibitors, which enhance the cytotoxicity of known antineoplastic agents. However, while many compounds have been proven to be very efficient in inhibiting Pgp activity only some of them are able to inhibit MRP1. The other likely approach is based on the design and synthesis of new non-cross-resistant drugs with physicochemical properties favoring the uptake of the drug by the resistant cells. The intracellular drug retention influences its cytotoxic effect. The level of the intracellular drug content is a function of the amount of drug transported inside the cell (influx) and the amount of drug expelled from the cell (efflux). In this work, the kinetics of drug uptake and the kinetics of active efflux of several anthracycline derivatives in both Pgp expressing K562/Adr cells and MRP1 expressing GLC4/Adr cells was determined. Our data have shown that in both cell lines there is no correlation between the resistance factor and the kinetics of drug efflux by these pumping systems. However, a very good correlation between the resistance factor and the kinetics of drug uptake has been established in both cell lines: the resistance factor decreases when the kinetics of drug uptake increases. This work has clearly shown that when the rate of transmembrane transport of anthracycline is high enough, the efflux mediated by the protein transporter is not able to pace with it. The protein transporter essentially operates in a futile cycle and the resistance factor is tending to one. It does not mean, however, that when the resistance factor is close to one the anthracycline is not transported by the pump.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395948     DOI: 10.1016/s0167-4889(99)00060-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

1.  Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.

Authors:  William Guerrant; Vishal Patil; Joshua C Canzoneri; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2012-02-13       Impact factor: 7.446

2.  Decrease of P-glycoprotein activity in K562/ADR cells by MbetaCD and filipin and lack of effect induced by cholesterol oxidase indicate that this transporter is not located in rafts.

Authors:  Paiboon Reungpatthanaphong; Carole Marbeuf-Gueye; Laurence Le Moyec; Milena Salerno; Arlette Garnier-Suillerot
Journal:  J Bioenerg Biomembr       Date:  2004-12       Impact factor: 2.945

3.  Anthrapyridones, a novel group of antitumour non-cross resistant anthraquinone analogues. Synthesis and molecular basis of the cytotoxic activity towards K562/DOX cells.

Authors:  J Tarasiuk; B Stefańska; I Plodzich; K Tkaczyk-Gobis; O Seksek; S Martelli; A Garnier-Suillerot; E Borowski
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

4.  Evidence against a role of P-glycoprotein in the clearance of the Alzheimer's disease Aβ1-42 peptides.

Authors:  Ivan Bello; Milena Salerno
Journal:  Cell Stress Chaperones       Date:  2015-01-16       Impact factor: 3.667

5.  Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages.

Authors:  Jean-Michel Michot; Cristina Seral; Françoise Van Bambeke; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

6.  Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages.

Authors:  Cristina Seral; Jean-Michel Michot; Hugues Chanteux; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

7.  Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia.

Authors:  Ping Ma; Xiaowei Dong; Courtney L Swadley; Anshul Gupte; Markos Leggas; Harry C Ledebur; Russell J Mumper
Journal:  J Biomed Nanotechnol       Date:  2009-04       Impact factor: 4.099

8.  Kinetic analysis of rhodamines efflux mediated by the multidrug resistance protein (MRP1).

Authors:  Chantarawan Saengkhae; Chatchanok Loetchutinat; Arlette Garnier-Suillerot
Journal:  Biophys J       Date:  2003-09       Impact factor: 4.033

9.  The effects of anthracycline drugs on the conformational distribution of mouse P-glycoprotein explains their transport rate differences.

Authors:  P H Nguyen; K P Sigdel; K G Schaefer; G A K Mensah; G M King; A G Roberts
Journal:  Biochem Pharmacol       Date:  2020-01-16       Impact factor: 5.858

10.  An ELISA-based procedure for assaying proteins in digests of human leukocytes and cell lines, using specifically selected peptides and appropriate antibodies.

Authors:  Ori Braitbard; Janette Bishara-Shieban; Hava Glickstein; Miriam Kott-Gutkowski; Umberto Pace; Deborah G Rund; Wilfred D Stein
Journal:  Proteome Sci       Date:  2006-06-21       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.